Valuation: StemRIM

Market Cap 18.68B 119M 104M 97.98M 88.97M 167M 11.42B 167M 1.17B 453M 5.81B 447M 437M P/E 2024
-13.6x
P/E 2025 -10.2x
Enterprise Value 11.68B 74.44M 64.91M 61.29M 55.66M 104M 7.14B 105M 734M 283M 3.63B 280M 273M EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
52.06%
Yield 2024 *
-
Yield 2025 -
1 day+3.51%
1 week-25.94%
Current month-46.69%
1 month-49.14%
3 months-41.00%
6 months-41.78%
Current year-32.70%
1 week 169
Extreme 169
187
1 month 169
Extreme 169
368
Current year 169
Extreme 169
368
1 year 169
Extreme 169
368
3 years 169
Extreme 169
793
5 years 169
Extreme 169
1,518
10 years 169
Extreme 169
1,518
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 66 01/10/2022
Chief Executive Officer 58 25/10/2023
Chief Administrative Officer - -
Director TitleAgeSince
Director/Board Member 66 01/02/2007
Director/Board Member 58 01/03/2019
Director/Board Member 54 01/10/2019
Change 5-day change 1-year change 3-year change Capi.($)
+3.51%-25.94%-41.58%-77.07% 68.79M
-0.08%+0.56%+31.26%-4.69% 78.83B
-1.11%+3.59%-12.67%-34.40% 60.48B
-2.39%+7.36%+507.33%+48.42% 63.11B
+0.14%-1.76%-10.86%+24.38% 46.75B
-0.24%+1.22%+2.26%+151.03% 45.66B
-0.70%+0.21%+51.31%-14.09% 32.37B
-0.56%+5.07%+48.40%+114.46% 25.87B
+0.47%+2.38%+0.10%+146.43% 21.33B
+0.27%+1.96%+62.19%+102.81% 15.8B
Average -0.05%+0.21%+63.77%+45.73% 39.03B
Weighted average by Cap. -0.63%+3.93%+95.33%+40.72%

Financials

2024 2025
Net sales - -
Net income -2.02B -12.88M -11.23M -10.61M -9.63M -18.04M -1.24B -18.12M -127M -49.03M -628M -48.39M -47.31M -1.93B -12.29M -10.72M -10.12M -9.19M -17.21M -1.18B -17.29M -121M -46.77M -600M -46.16M -45.14M
Net Debt -8.41B -53.58M -46.72M -44.11M -40.06M -75.05M -5.14B -75.37M -528M -204M -2.61B -201M -197M -6.99B -44.56M -38.85M -36.69M -33.31M -62.42M -4.28B -62.68M -439M -170M -2.17B -167M -164M
Logo StemRIM
StemRIM Inc. is a Japan-based company mainly engaged in the regenerative medicine business. The Company is engaged in the development and research of medicines based on new action mechanism to promote functional regeneration and healing of biological tissue damaged and lost function due to injury or illness. The Company’s main product is stem cell regeneration-inducing medicine. The stem cell regeneration-inducing medicine is a medicine which can obtain the same therapeutic effect as regenerative medicine only by administering the medicine without using living cells and tissues.
Employees
-
Date Price Change Volume
18/09/26 JPY 177.00 +3.51% 520,300
17/09/26 JPY 171.00 -3.39% 893,000
16/09/26 JPY 177.00 -1.67% 638,600
15/09/26 JPY 180.00 -1.10% 1,283,900
14/09/26 JPY 182.00 +1.11% 1,952,700
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 4599 Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!